Company intelligence / Profile preview
Chimeric Therapies
Carlton, Victoria, Australiachimerictherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Chimeric Therapeutics has three assets in Phase 1/1b clinical trials, including two Auto-CAR-Ts (one for GI cancers and another for Glioblastoma) and an off-the-shelf ALLO NK platform being tested in AML. The company is expecting a Phase 1 readout for CHM CDH17 at Dose level 2 in June 2025.
- Therapeutic areas
- Oncology
- Modalities
- CAR T cell therapyNK cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Chimeric Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimeric Therapies.